评估卡培他滨维持治疗中晚期胃癌患者的安全性可行性及临床疗效

Safety,Feasibility,and Efficacy of Capecitabine Maintenance in Patients With Advanced Gastric Cancer

目的 观察卡培他滨维持治疗中晚期胃癌患者的近期临床疗效和不良反应.方法 本研究共22例患者,所有患者接受多西他赛,顺铂,5-氟尿嘧啶传统一线化疗方案后疾病无进展,给予卡培他滨维持治疗,剂量为1000 mg/m每天两次,连服2周后休息1周,再开始下一个周期治疗,当出现严重的毒副反应或疾病进展才准予停药.结果 所有患者卡培他滨维持治疗的中位周期数为5（2 -14）,平均随访20个月,所有患者进展,18例死亡,中位PFS为10.3个月（范围7.9-16.4个月）,中位OS为18.6个月（范围8.7 -33.2个月）.1年生存率69.9％,2年OS 34.7％.住院治疗期间没有发生1例治疗毒性相关性死亡.住院治疗期间没有发生1例治疗毒性相关性死亡,只有2例患者出现Ⅲ级.手足综合症,其他毒性均为Ⅰ、Ⅱ级毒性反应.结论 卡培他滨维持治疗,对于晚期胃癌患者行一线化疗后无进展者,是可行的.

Objective： of capecitabine in the maintenance？ treatment of？ advanced gastric cancer patients in recentclinical？ curative effect and. adverse reaction. Methods： In this study,included 11 patients with AGC, Patients without pro-gression after firstline chemotherapy that include docetaxel, cisplatin, and 5 - fluorouracil were eligible for capecitabine ma-intenance. The maintenance dose of eapecitabine was 1000 mg/m2 twice daily for 14 days and 7 days break before the be-ginning of next cycle, when the progress of toxicity or serious diseases can be stopped. Result ： The median number of cy-cles of maintenance capecitabine received was 5 （2 -14）. During a median follow - up of 20 months, all patients pro-gressed and 18 patients died. Median PFS was 10. 3 months （ range, 7.9 - 16.4 months） , and median OS is 18. 6 months（ range, 8. 7- 33.2 months）. The 1 - year survival rate was 69. 9%, and 2 - year OS was 34% No death or hospitalizationfor capecitabine toxicity was noted. In all, 2 patient developed grade III hand foot syndrome. Other toxieities were grade.Ⅰ-Ⅱ toxicity. Conclusion： maintenance therapy with capecitabine, in patients with AGC who do not progress on first - linechemotherapy, is feasible.